You are here: 
text zoom : S | M | L
Printer Friendly Version
Contact Details

Centre for Reproductive Health
THE UNIVERSITY OF ADELAIDE
SA 5005
AUSTRALIA
Email

Telephone: +61 8 8313 4094
Facsimile: +61 8 8303 4099

Serving the Community and Supporting Industry

The Research Centre for Reproductive Health focuses on research with a Clinical and Commercial Interface.

RCRH has generated intellectual property technology that is subject to licence or commercialisation.  Some of the Centre's achievements include negotiating  Consulting Contracts,  Industry Research Grants,  Industry Sponsored collaboration Research Agreements and a spin off company start up with Reproductive Health Sciences Pty Ltd.

RCRH has worked closely with Repromed and has active relationships with other clinical organisations to identify research needs and implement research findings.  Researchers also have strong links and partnerships with companies in the human and animal assisted reproduction industry to develop novel therapeutics, devices and diagnostics.

RCRH has a number of senior researchers experienced in translation of research findings into biomedical applications.

RCRH members hold a number of patents that have helped to initiate partnerships with industry and create spin out companies.

Collaboration and Networks

Strong linkages and associations with other leading organisations in the area of developmental and reproductive health has allowed RCRH to:

  • Enhance interdisciplinary links
  • Provide viable connections between research and clinical needs
  • Provide an interface between research and commercial interests

RCRH Research Commercialisation

RCRH Member

Relevant Research

Clinical and Health Benefits

Industry
Partner 

Jeremy Thompson & Robert GilchristDevelopment of bovine and human oocyte IVM mediaIVF Procedure EfficiencyCook Australia
Kelton TremellenOSMI Study Effect of novel anti-oxidant on sperm function  Roche Diagnostic &  Repromed
Sarah RobertsonMethod & Medium for In Vitro FertilisationIVF Procedure EfficiencyMediCult
David KennawayLicence agreement to market Melatonin Antibodies Buhlmann Laboratories
Claire RobertsIGF-II use in embryo culture media for ART A media formulation to improve implantation rate, placental morphogenesis and pregnancy outcomes following IVF/ICSIMediCult
Clarie RobertsIGF-II as a therapeutic for use in women at risk of major pregnancy complicationsTherapeutic to enhance placental morphogenesis and prevent or minimise pregnancy complications